Published January 1992
by Royal Society of Medicine Press Ltd .
Written in English
|The Physical Object|
|Number of Pages||72|
A head-to-head comparison of ziprasidone or risperidone combined with clozapine revealed similar immediate and long-term efficacy on treatment-resistant schizophrenic symptoms at a diverging range of side effects regarding serum prolactin, extrapyramidal symptoms, and QTc-prolongation (Kuwilsky et al., ; Zink et al., ).Cited by: Clozapine is often referred to as a “gold-standard” medication for treatment-resistant psychosis; however, estimates suggest that at least 40 percent of patients treated with clozapine do not show an adequate response (at least a 20 percent reduction in their Positive and Negative Syndrome Score [PANSS] or similar assessment) (1). In this chapter, I outline a sequential approach to treatment-resistant schizophrenia. An important first step is to rule out “pseudo-refractoriness,” most commonly due to insufficient adherence. Therapeutic drug monitoring and a long-acting injectable trial are key tools to correctly establishing treatment : Oliver Freudenreich. For this reason, clozapine did not enter the United States until it was approved by the FDA in Defining “Treatment-Resistant” Schizophrenia. Clozapine was approved largely due to the work of John Kane. In his work, Kane helped define “treatment-resistant” schizophrenia, and ultimately the context in which clozapine has proven.
Although clozapine is considered the standard pharmacotherapy and the last resort in the management of treatment-resistant schizophrenia, 40% to 70% of patients with treatment-resistant schizophrenia fail to respond to clozapine treatment. 8,24 Clozapine-resistant schizophrenia characteristics include persistent active psychotic features. that clozapine was no better than other antipsychotics in the treatment of refractory schizophrenia. Thus, a modern evidenced-based technique concluded that clinicians’ observations over nearly 30 years were wrong. The ques-tion that arises is this: is clozapine really not the drug we have believed it to be over decades of widespread use or is. A one-stop shop, covering everything a doctor, teacher or trainee will ever need to know about neuropsychopharmacology. Siskind, D, Siskind, V, Kisely, S () Clozapine response rates among people with treatment-resistant schizophrenia: Data from a systematic review and meta-analysis. Can J .
Clozapine-resistant schizophrenia: A positive approach - Volume Issue 3 - Lisa Williams, Graham Newton, Kathryn Roberts, Sara Finlayson, Clare BrabbinsCited by: Although treatment-resistant schizophrenia (TRS) was described 50 years ago and has a gold standard treatment with clozapine based on well-defined criteria, there is still a matter of great. Background: Clozapine has been used in treatment-resistant patients with schizophrenia. However, only 40% of patients with treatment-resistant schizophrenia have response to clozapine. Many augmentation strategies have been proposed to treat those clozapine-resistant patients, but the results are inconclusive. ABSTRACTIntroduction: Clozapine was first introduced as an antipsychotic in the ‘s but a cluster of deaths, later linked to the drug’s risk of agranulocytosis, led to its withdrawal in most countries. However, work in the ’s established its unique efficacy in treatment resistant schizophrenia (TRS), which constitutes as many as 30% of those with the illness.